Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Langer

Showing results (511-520 of 596) with videos related to

Pageof 60
Sort By:
JTO Clinical and Research Reports|September 6, 2022
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory <i>ALK</i>+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) TrialsScott N Gettinger, Rudolf M Huber, Dong-Wan Kim, et al.
Neurosurgery|June 16, 2025
A Multicenter Study of Noninvasive Wireless Assessment of Cerebrospinal Fluid Shunt Function in Hydrocephalus PatientsDavid D Limbrick, Jesse Skoch, Kurtis Auguste, et al.
Transplantation and Cellular Therapy|April 26, 2025
Coronary Artery Calcification as a Predictor of Survival in Patients Receiving Post-transplant Cyclophosphamide for GVHD ProphylaxisChristopher Graham, Anmol Baranwal, Bas Kietselaer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2020
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung CancerCharu Aggarwal, Jeffrey C Thompson, Austin L Chien, et al.
JAMA Oncology|October 17, 2018
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung CancerCharu Aggarwal, Jeffrey C Thompson, Taylor A Black, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 16, 2023
Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidationNikhil Yegya-Raman, Sang Ho Lee, Cole Friedes, et al.
Clinical Lung Cancer|May 19, 2018
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and TechnologiesFred R Hirsch, Keith M Kerr, Paul A Bunn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2018
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancerP D Bonomi, D Gandara, F R Hirsch, et al.
Clinical and Translational Radiation Oncology|January 24, 2023
Death without progression as an endpoint to describe cardiac radiation effects in locally advanced non-small cell lung cancerNikhil Yegya-Raman, Timothy P Kegelman, Sang Ho Lee, et al.
Journal for Immunotherapy of Cancer|October 6, 2023
Neoantigen-specific CD4<sup>+</sup> tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patientsMacLean S Hall, Jamie K Teer, Xiaoqing Yu, et al.
Pageof 60

Showing results (511-520 of 596) with videos related to

Sort By:
Pageof 60
JTO Clinical and Research Reports|September 6, 2022
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory <i>ALK</i>+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) TrialsScott N Gettinger, Rudolf M Huber, Dong-Wan Kim, et al.
Neurosurgery|June 16, 2025
A Multicenter Study of Noninvasive Wireless Assessment of Cerebrospinal Fluid Shunt Function in Hydrocephalus PatientsDavid D Limbrick, Jesse Skoch, Kurtis Auguste, et al.
Transplantation and Cellular Therapy|April 26, 2025
Coronary Artery Calcification as a Predictor of Survival in Patients Receiving Post-transplant Cyclophosphamide for GVHD ProphylaxisChristopher Graham, Anmol Baranwal, Bas Kietselaer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2020
Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung CancerCharu Aggarwal, Jeffrey C Thompson, Austin L Chien, et al.
JAMA Oncology|October 17, 2018
Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung CancerCharu Aggarwal, Jeffrey C Thompson, Taylor A Black, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 16, 2023
Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidationNikhil Yegya-Raman, Sang Ho Lee, Cole Friedes, et al.
Clinical Lung Cancer|May 19, 2018
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and TechnologiesFred R Hirsch, Keith M Kerr, Paul A Bunn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2018
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancerP D Bonomi, D Gandara, F R Hirsch, et al.
Clinical and Translational Radiation Oncology|January 24, 2023
Death without progression as an endpoint to describe cardiac radiation effects in locally advanced non-small cell lung cancerNikhil Yegya-Raman, Timothy P Kegelman, Sang Ho Lee, et al.
Journal for Immunotherapy of Cancer|October 6, 2023
Neoantigen-specific CD4<sup>+</sup> tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patientsMacLean S Hall, Jamie K Teer, Xiaoqing Yu, et al.
Pageof 60